Abstract: Injectable water-in-oil emulsion possessing immunity adjuvant activity and which can be used in man and animals as vaccine or an immunological medicament comprising an oily phase comprising an oil , an aqueous phase and at least one emulsifier, wherein the oil of said oily phase is a substantially metabolizable oil or a mixture of substantially metabolizable oils and said emulsifiers or emulsifiers providing with said metabolizable oil a stable emulsion having immunity adjuvant activity and a viscosity of less than 400 mPa.s at 25° C.

Abstract: The invention comprises the nucleotide sequences comprising the FIPV S gene, or a fragment of this gene, which are modified in at least one of the antigenic regions A1 and A2 which are involved in enhancement, as well as the use of these sequences for the expression of modified proteins, and for the construction of recombinant viruses or expression plasmids, and the use of the recombinant viruses as vaccines against feline infectious peritonitis, the use of the expression plasmids as immunizing composition by direct injection of the said plasmids into cats, and the use of the modified proteins as vaccine.

Abstract: The live recombinant avian vaccine comprises, as vector, an avian herpesvirus comprising at least one nucleotide sequence coding for and expressing an antigenic polypeptide of an avian pathogenic agent, inserted into the region lying between the ATG of ORF UL55 and the junction of U.sub.L with the adjacent repeat region, under the control of the CMV immediate early promoter. The vector is preferably chosen from the group consisting of Marek's disease viruses (MDV and HVT), infectious laryngotracheitis virus ILTV and herpes of ducks. A polyvalent vaccine formula comprises at least two vaccines of this type, with different inserted sequences.

Abstract: Various genes of herpes virus of turkeys (HVT), Marek's disease virus (MDV) and infectious laryngotracheitis virus (ILTV) have been identified as non-essential regions (and candidates for insertion sites for foreign genes) and/or as antigen-encoding regions. The former include the HVT homologue of the HSV (herpes simplex virus) gC gene, the TK (thymidine kinase) region of MDV or ILTV, ORF3 of ILTV (as defined herein), the ribonucleotide reductase (large subunit) gene of ILTV, MDV or HVT and the ribonucleotide reductase (small subunit) gene of MDV. The antigen-encoding regions include the HVT homologues of the HSV gB, gC and gH genes, the ILTV homologue of HSV gB, ORF2 of ILTV, and the HVT homologue of the HSV-1 immediate early genes IE-175 and IE-68. Manipulation of these genes allows vaccines to be prepared comprising attenuated virus or virus carrying heterologous antigen-encoding sequences.

Abstract: A vaccine effective against Marek's disease virus (MDV) comprises (a) an MDV attenuated by virtue of being TK- or (b) a host expressing an MDV antigen, namely the respective MDV homologues of the HSV gB, gC, gD or gH glycoproteins (or antigenic parts thereof) or the respective MDV homologues of the HSV-1 immediate early genes IE-68 or IE-175. The host may be a herpes virus of turkeys (HVT), more particularly HVT in which the MDV antigen is inserted in the HVT homologue of the HSV gC gene, the ribonucleotide reductase (large subunit) gene or the thymidine kinase (TK) gene.

Abstract: Various genes of herpes virus of turkeys (HVT), Marek's disease virus (MDV) and infectious laryngotracheitis (ILTV) have been identified as non-essential regions (and candidates for insertion sites for foreign genes) and/or as antigen encoding regions. The former include the HVT homologue of the HSV (herpes simplex virus) gC gene, the TK (thymidine kinase) region of MDV or ILTV, ORF3 of ILTV (as defined herein), the ribonucleotide reductase (large subunit) gene of ILTV, MDV or HVT and the ribonucleotide reductase (small subunit) gene of MDV. The antigen-encoding regions include the HVT homologues of the HSV gB, gC and gH genes, the ILTV homologue of HSV gB, ORF2 of ILTV, and the HVT homologue of the HSV-1 immediate early genes IE-175 and IE-68. Manipulation of these genes allows vaccines to be prepared comprising attenuated virus or virus carrying heterologous antigen-encoding sequences.

Abstract: Collar or other external device for a pet, in particular a cat or dog, made of a matrix in which is incorporated from 0.1 to 40% by weight, preferably from 1 to 15 % by weight, relative to the external device, of a substance which is active against ectoparasites such as fleas and ticks, this active substance being formed of at least one compound corresponding to formula (I) below: ##STR1## this collar or other external device being designed to ensure more than 6 months of efficacy against fleas and more than 3 months of efficacy against ticks, the efficacy being maintained for several weeks even if the collar or other external device is taken off or lost or if there is a variation in the release of the compound.

Abstract: A method for orally administering medicaments to a plurality of animal drinking stations, and an apparatus for accomplishing the method. A medicament reservoir is separately connected to each of the drinking stations via tubes each of an identical predetermined diameter. Medicament is allowed to flow through each of the tubes to each drinking station. Substantially identical rate of medicament flow to each drinking station is insured by the identical predetermined diameter of each of the tubes.

Abstract: A vaccine effective against Marek's disease virus (MDV) comprises (a) an MDV attenuated by virtue of being TK- or (b) a host expressing an MDV antigen, namely the respective MDV homologues of the HSV gB, gC, gD or gH glycoproteins (or antigenic parts thereof) or the respective MDV homologues of the HSV-1 immediate early genes IE-68 or IE-175. The host may be a herpes virus of turkeys (HVT), more particularly HVT in which the MDV antigen is inserted in the HVT homologue of the HSV gC gene, the ribonucleotide reductase (large subunit) gene or the thymidine kinase (TK) gene.

Abstract: The medicinal product comprises as active principle a melarsomine hydrochloride preparation having a purity of between 98.5 and 100%. The process for obtaining this preparation is stated essentially as follows:step 1, trichlorotriazine (TCT) is converted to diaminochlorotriazine (DCT) in an ammoniacal medium;step 2, the DCT is converted to melarsen acid hydrochloride (MAH) in the presence of arsanilic acid;step 3, the MAH is reduced to melarsen oxide dihydrate; andstep 4, the melarsen oxide dihydrate is converted to melarsomine dihydrochloride in the presence of cysteamine hydrochloride. In each step, a purified preparation of the corresponding intermediate product, or final product in step 4, is obtained.

Abstract: A method for vaccination against haemorrhagic dysentery of pigs with a vaccine including an effective quantity of inactivated and adjuvant-containing Serpulina hyodysenteriae antigen which is administered intradermally, it being possible for the vaccine to be especially formulated in a dose volume of between about 0.1 and 0.3 ml, especially of the order of 0.2 ml. A vaccination kit for administration of the vaccine may include, for example a pressurized jet administering apparatus, designed for the intradermal administration of individual doses of vaccine and combined with a supply source containing a vaccine of this type.

Abstract: The therapeutic elements for oral administration of medication to animals comprise an active principle contained in a craved for envelope. The envelope (1) comprises, in admixture, one or more craved for materials and one or more substances agglomerating the craved for materials, the envelope possessing a high mechanical and thermal resistance, and being previously formed into a hollow shape appropriate for consumption by the animal, and defining an internal volume, such internal volume being filled by a craved for binder (3) and comprising the active principle (2), the binder closely conforming the internal shape of the envelope (1) in order to provide a continuity between the envelope (1) and the active principle (2).

Abstract: A vaccine effective against Marek's disease virus (MDV) comprises (a) an MDV attenuated by virtue of being TK- or (b) a host expressing an MDV antigen, namely the respective MDV homologues of the HSV gB, gC, gD or gH glycoproteins (or antigenic parts thereof) or the respective MDV homologues of the HSV-1 immediate early genes IE-68 or IE-175. The host may be a herpes virus of turkeys (HVT), more particularly HVT in which the MDV antigen is inserted in the HVT homologue of the HSV gC gene, the ribonucleotide reductase (large subunit) gene or the thymidine kinase (TK) gene.

Abstract: The present invention relates to vaccines for avian use which are based on live recombinant avian herpesviruses, in particular the Marek's disease viruses including HVT virus (herpesvirus of turkey), in which has been inserted, by genetic recombination, at least one nucleotide sequence which encodes and expresses an antigenic polypeptide of an avian pathogen under conditions which ensure immunization leading to efficient protection of the vaccinated animal against the pathogen. In one embodiment, the antigenic polypeptide is inserted in the UL43 gene under the control of the CMV immediate early promoter. The vaccines of the present invention are advantageous over previously used vaccines in that they can be used to ensure total protection of animals against Gumboro disease and to immunize chicks as young as one-day old without secondary effects, and only require low doses.

Abstract: Water miscible pharmaceutical compositions containing up to about 40% of erythromycin prepared by reaction with acetic acid in a non-aqueous water miscible organic solvent system.

Abstract: Herpesviruses naturally deficient in gD, that is to say not expressing their gD gene in vitro or not possessing this gene, are transformed to express gD in vitro. This transformation by genetic recombination can consist in replacement of the natural promoter by another one or insertion of an expression cassette containing gD and a promoter. The invention also relates to these viruses incorporating a gene coding for an antigen of interest, to the vaccines obtained and to the methods of culture thus improved. The invention relates in particular to avian herpesviruses, especially MDV, and the VZV virus.

Abstract: The invention is directed to a method of detecting infection of a blood sample by various strains of bovine diarrhoea virus (BVD) including a first test wherein anti-bovine diarrhoea virus antibodies are detected by means of a recombinant antigen comprising the BVD p80 protein expressed by a eukaryotic host and a second test wherein viral particles are detected by means of antibodies directed against the BVD p80 viral protein. The method is particularly useful in detecting pathogenic conditions such as persistent viremias and acute infections caused by BVD viruses, and is particularly advantageous because it is an extremely sensitive and efficient test and because it is capable of detecting infections caused by any one of a wide variety of BVD strains. The recombinant antigen employed in the method is preferably encoded by the nucleotide sequence listed as SEQ ID No: 1.

Abstract: The invention is directed to a method of detecting infection of a blood sample by various strains of bovine diarrhoea virus (BVD) including a first test wherein anti-bovine diarrhoea virus antibodies are detected by means of a recombinant antigen comprising the BVD p80 protein expressed by a eukaryotic host and a second test wherein viral particles are detected by means of antibodies directed against the BVD p80 viral protein. The method is particularly useful in detecting pathogenic conditions such as persistent viremias and acute infections caused by BVD viruses, and is particularly advantageous because it is an extremely sensitive and efficient test and because it is capable of detecting infections caused by any one of a wide variety of BVD strains. The recombinant antigen employed in the method is preferably encoded by the nucleotide sequence listed as SEQ ID No: 1.

Abstract: The medicinal product comprises as active principle a melarsomine hydrochloride preparation having a purity of between 98.5 and 100%. The process for obtaining this preparation is stated essentially as follows:step 1, trichlorotriazine (TCT) is converted to diaminochlorotriazine (DCT) in an ammoniacal medium;step 2, the DCT is converted to melarsen acid hydrochloride (MAH) in the presence of arsanilic acid;step 3, the MAH is reduced to melarsen oxide dihydrate; andstep 4, the melarsen oxide dihydrate is converted to melarsomine dihydrochloride in the presence of cysteamine hydrochloride. In each step, a purified preparation of the corresponding intermediate product, or final product in step 4, is obtained.

Abstract: Two joint agents responsible for the disease called Mystery Disease have been isolated. Compositions comprising purified viral particles of Mystery Disease virus (A) and/or purified viral particles of Mystery Disease virus (B), and an appropriate vehicle have been described.